April 2016 FDA Recall Cisatracurium by Fresenius Kabi Usa, Llc
D-0819-2016 - Incorrect/ Undeclared Excipient

This Class II drug recall was voluntarily initiated by Fresenius Kabi Usa, Llc on April 5, 2016 for the product Cisatracurium. The FDA reported the reason for recall as incorrect/ undeclared excipient. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0819-2016

Reason for Recall
Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Preservative free on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.
Initiated
04-05-2016
Reported
04-20-2016
Quantity
94,560 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Fresenius Kabi USA, LLC
Nationwide and Puerto Rico
Cisatracurium Besylate Injection, 20 mg per 10 mL (2 mg per mL), For intravenous injection, 10 mL Multiple Dose Vial, Rx only, Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-417-10

Batch or Lot Expiration Information

Lot# : 6010157, Exp. 01/2017